SCr changes in Phase 3 studies. (A) Mean (±SE) change from baseline in SCr (mg/dl) across the Phase 3 program (0 to 12 months). (B) SCr outliers during tofacitinib 5 mg BID treatment. (C) SCr outliers during tofacitinib 10 mg BID treatment.
Isaacs et al. Arthritis Research & Therapy 2014 16:R158 doi:10.1186/ar4673